20 20 Gene Systems

Executive Summary

20/20 GeneSystems, Inc. is a clinical laboratory test developer focused on Al-powered blood tests for the early detection and prevention of cancers and chronic diseases. We are currently the #2 market leader in the U.S. for multi-cancer early detection (MCED) blood tests. Our flagship product, OneTest™ for Multiple Cancers, is seeing rapid adoption in the MCED marketplace with ten consecutive quarters of accelerated sales growth.

The Problem: Screening is not widely available or utilized for most of the leading cancer killers, such as those of the lungs, pancreas, ovaries, and liver. To address this void, MCEDs are now available and generating significant enthusiasm among many medical authorities, policy makers, employers, and consumers. Up until now, these tests have been expensive, hard to access, and miss most cancers at their earlier stages when they can often be effectively treated.

Our Solution & Advantages: OneTest™ is the first and only MCED on the market that (i) is available for under $200, (ii) can be accessed at home without painful needles, and (iii) has been demonstrated in studies conducted in 2024 by the U.S. National Cancer Institute to correctly identify significant numbers of otherwise deadly cancers at an early stage. These cancers include those of the lung, pancreas, and ovaries, which, when detected at an earlier stage, give the best chance of survival.

The Market: In the U.S. alone, the market for MCEDs is expected to exceed several billion dollars per year by the end of this decade following anticipated coverage by Medicare starting in 2028. There is also a substantial overseas market, especially throughout East Asia where demand for new types of early cancer screening is high.

Our Progress:

• Over 15,000 tests sold in the past three years.
• Revenues doubling yearly; 10 consecutive quarters of increasing sales growth.
• Line-of-sight to profitability.
• Growing adoption among employers and consumers.
• Additional revenues already coming from license agreement w/ clinical testing laboratories in Taiwan and Japan.

New Products: Al powered OneTest for Longevity will track biomarkers of chronic inflammation associated with 8 of 10 leading causes of death and offer specific diet and exercise changes proven to lower biomarker levels and related disease risk.